Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves

Novo Nordisk – Setting a strategic course in turbulent times

Three global megatrends are emerging in the healthcare sector: longevity, prevention, and self-care. Novo Nordisk is positioning itself cleverly here by marketing its blockbusters, such as Ozempic and Wegovy, not only as diabetes therapies but as solutions for a healthier, longer life. The focus is shifting from repair medicine to the prevention of serious secondary diseases. In addition, the treatments also address mental well-being, which is in line with changing patient expectations for holistic health. This strategic orientation ensures relevant growth for the Company beyond the pure diabetes segment.

Novo Nordisk has just made a clear statement with its billion-dollar acquisition of Akero Therapeutics for up to USD 5.2 billion. The biotech company brings with it the active ingredient efruxifermin, which has already delivered promising results in the advanced liver disease MASH. This could be a real game-changer, especially for patients with cirrhosis of the liver. This move diversifies the pipeline beyond GLP-1 drugs and opens up a new, large therapeutic area. If the Phase 3 study is successful, Novo Nordisk could secure a significant first-mover advantage in a largely underserved market.

At the same time, political pressure in the US on drug prices is causing uncertainty. Former President Trump's announcement that he would massively reduce the cost of GLP-1 drugs is weighing on sentiment in the short term. In the long term, however, such a price reduction could also be an opportunity. It would facilitate access for significantly more patients and accelerate the market penetration of the drugs. For Novo Nordisk, the task now is to defend its margins even in a more price-sensitive environment through operational efficiency and economies of scale in production. The austerity measures it has embarked upon are a necessary prerequisite for this. The share price is currently trading at EUR 46.835.

PanGenomic Health – Capitalizing on major health trends

Medicine is undergoing a transformation. Instead of treatment, the future is focused on prevention. PanGenomic Health is driving this change with its NaraCare.AI platform, which is scheduled to launch in the fourth quarter of 2025. This technology combines AI-supported diagnostics with telemedicine and analyzes individual health data to create personalized prevention plans. This model offers an attractive alternative, especially in the price-sensitive North American market. In addition, political changes under US Health Secretary Robert F. Kennedy Jr. favor the recognition of such complementary medicine approaches, which substantially improves PanGenomics' market opportunities.

PanGenomic is responding to the boom in mental health and self-optimization with a cleverly linked ecosystem. At its core is the Nara Mental Health App, which helps users document symptoms and provides evidence-based recommendations for herbal therapies. This offering is directly integrated with the Agenta Health e-commerce store, which was launched in August 2025. Customers can purchase the appropriate, personalized health products directly through this store. This seamless integration of diagnostics, counseling, and sales creates a closed loop for health-conscious consumers who are increasingly taking responsibility for their own health. At the same time, the data can be used for the development of NaraCare.AI.

To compete in the race for longevity, a solid database is needed. This is where PanGenomic comes in with an ambitious global initiative. Through its subsidiary Mindleap Health, the Company is establishing a real-world evidence data center in Hong Kong, which is scheduled to begin operations in the fourth quarter of 2025. This center will collect health data from Western and Asian sources and evaluate it using AI analytics. The goal is to substantiate the scientific evidence for non-pharmaceutical therapies and thus build a decisive knowledge advantage in the multi-billion-dollar longevity market. Since the beginning of May, the stock has gained more than 1,600% at its peak. After consolidation, the stock is currently trading at CAD 1.50.

Pfizer – How the pharmaceutical giant is capitalizing on the new megatrends

Investors would do well to look beyond the quarterly figures. Pfizer is strategically positioning itself in three key growth areas. The Company is addressing the global battle for longevity through massive investments in oncology and innovative therapies designed to improve quality of life in old age. It is also driving the shift from curative to preventive medicine, for example through vaccines and digital tools for personalized prevention. Thirdly, Pfizer is responding to the boom in self-care and mental health with campaigns and the development of appropriate therapies. These steps demonstrate a clear focus on the biggest long-term market opportunities.

Pfizer is currently making headlines with two significant maneuvers. The planned acquisition of Metsera for up to USD 5.2 billion secures the Company's entry into the lucrative obesity market. This move follows prior setbacks and aims to establish a new growth pillar. At the same time, Pfizer has reached a pragmatic agreement with the US government. Significant price reductions for certain drugs in exchange for a three-year exemption from tariffs. This deal reduces trade policy risks but weighs on margins in the short term. At the same time, recent FDA restrictions on COVID vaccines highlight the ongoing regulatory challenges.

The upcoming quarterly figures will provide more clarity. Analysts expect a decline in profits due to price reductions. In the long term, however, Pfizer is presenting itself as a company in transition. Its extensive pipeline, strengthened by acquisitions, and its focus on future markets such as obesity are promising. The current valuation appears moderate relative to industry peers. For value-oriented investors with a medium-term horizon, the current price could offer an opportunity to invest in a company that is strategically repositioning itself for the healthcare challenges of tomorrow. The share is currently trading at USD 24.51.

The structural shift toward preventive and personalized medicine is creating clear investment opportunities. Novo Nordisk is skillfully diversifying its GLP-1 blockbuster beyond diabetes into areas such as MASH, positioning itself as a holistic provider for longevity. PanGenomic Health is driving data-driven healthcare forward with its AI-powered platform for personalized prevention plans and opening up new markets. Pfizer is leveraging its financial strength for strategic acquisitions to decisively enter future fields such as the obesity market and realign its portfolio. These pioneers are making the megatrend tangible for investors.